問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Veterans General Hosptial (在職)

Division of Infectious Disease

Division of General Internal Medicine

更新時間:2023-09-19

陳垚生
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

42Cases

2010-11-15 - 2012-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2020-01-03 - 2021-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus
  • Condition/Disease

    AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Test Drug

    AR-301 Tosatoxumab

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites

2007-11-15 - 2008-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
24Sites

Terminated23Sites

Study ended1Sites

2008-12-08 - 2009-12-08

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2013-05-01 - 2017-09-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-02-01 - 2013-07-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2005-12-01 - 2007-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Study ended10Sites

2015-09-01 - 2017-12-31

Phase III

A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects with Community-Acquired Bacterial Pneumonia (CABP)
  • Condition/Disease

    The initial targeted indications are serious skin infections (ABSSSI), community acquired lower respiratory tract infections (CABP) and urinary tract infections

  • Test Drug

    Omadacycline (PTK 0796)

Participate Sites
5Sites

Terminated5Sites

2014-02-07 - 2015-07-30

Phase II/III

A Phase 3, multicenter, randomized, double-blind, active controlled study to evaluate the efficacy and safety of IV and oral delafloxacin compared with vancomycin + aztreonam in patients with acute bacterial skin and skin structure infections
  • Condition/Disease

    acute bacterial skin and skin structure infections

  • Test Drug

    Delafloxacin

Participate Sites
7Sites

Terminated7Sites

1 2 3 4 5